Start-Up Nation Finder

45 companies were selected

Add smartlist note (optional)

Smartlist name*

Smartlist must have a valid name.

Description (optional)

Hey #USER_FULLNAME#!

Claim #COMPANY_NAME# ’s profile to become an administrator with editing privileges in
#COMPANY_NAME# ’s page on Start-Up Nation Finder

The invitation to claim the profile was originally sent to

Hey #USER_FULLNAME#!

Claim #COMPANY_NAME# ’s profile to become an administrator with editing privileges in
#COMPANY_NAME# ’s page on Start-Up Nation Finder

Please provide us the following information. Note that you need to have an email in this organization in order to claim the profile.

Name*

Work Email* (please provide your email in the organization)

Position*

Notes

I agree to receive Informational Emails from Start-Up Nation Finder as defined in the Privacy Policy and Terms of Use

Already have an account?

Search Was Saved

Home > Companies > Beta-O2 Technologies

Claimed by owner • Last Update 17.4.2023 • Suggest Edits • Claim Profile

Claimed by owner

Beta-O2 Technologies

Implantable Bioreactor for Treating Type 1 Diabetes

www.jpost.com • Sep 12, 2019

https://www.jpost.com/Israel-News/Hillels-Tech-Corner-Using-tech-to-replicate-the-pancreas-601531

www.diabetes.co.uk • Apr 26, 2018

Positive breakthrough made in implanted islet cells technology - Diabetes

www.calcalistech.com • Dec 3, 2017

Japanese Technology Holding Company IRI Wants to Raise $30 Million in Tel Aviv IPO

www.globes.co.il • Aug 22, 2016

FDA decision boosts Beta-02's artificial pancreas

www.finsmes.com • Mar 30, 2015

Beta-O2 Technologies Receives Investment from Sherpa Innoventures - FinSMEs

www.israel21c.org • Nov 17, 2014

Beta-O2 testing cure for type 1 diabetes

www.globes.co.il • Oct 22, 2014

Beta-O2 starts clinical trial for artificial pancreas

www.diabetesdaily.com • Sep 10, 2014

Future Tech: Beta-O2 Announces Implantable Device to Automatically Manage Blood Sugars

Beta-O2 Technologies is a biomedical company developing a proprietary implantable bioreactor, the Air, for the treatment of patients with type 1 diabetes.

The Air is a small medical device that is implanted in a minimally invasive procedure. The device, which contains islets of Langerhans, is intended to free patients from insulin injections and continuous monitoring of glucose levels. The device also reduces the risk of hypoglycemic episodes and other complications of the condition.

Because the Air device contains living cells, the patient needs to refill the air in the device using a replenishing device, which includes a dedicated injector.